Group Gp Lp Column III Acquires 30,884 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III purchased 30,884 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The stock was bought at an average cost of $19.54 per share, for a total transaction of $603,473.36. Following the completion of the purchase, the insider directly owned 981,890 shares in the company, valued at $19,186,130.60. This represents a 3.25% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Thursday, December 4th, Group Gp Lp Column III acquired 5,266 shares of Surrozen stock. The shares were purchased at an average price of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III bought 315,457 shares of Surrozen stock. The shares were purchased at an average cost of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Trading Up 0.0%

SRZN stock traded up $0.01 during midday trading on Monday, reaching $20.47. The stock had a trading volume of 110,179 shares, compared to its average volume of 30,511. Surrozen, Inc. has a 52-week low of $5.90 and a 52-week high of $21.33. The company’s fifty day simple moving average is $13.90 and its 200 day simple moving average is $11.32. The company has a market cap of $175.45 million, a price-to-earnings ratio of -0.92 and a beta of 0.62.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The business had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. Sell-side analysts predict that Surrozen, Inc. will post -8.49 EPS for the current year.

Institutional Trading of Surrozen

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC lifted its position in Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after buying an additional 3,424 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after acquiring an additional 5,702 shares during the last quarter. Heights Capital Management Inc. purchased a new stake in shares of Surrozen in the 1st quarter valued at approximately $524,000. Woodline Partners LP acquired a new position in shares of Surrozen in the 3rd quarter worth approximately $621,000. Finally, Armistice Capital LLC purchased a new position in shares of Surrozen during the 2nd quarter worth approximately $536,000. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SRZN has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. Wall Street Zen raised Surrozen to a “sell” rating in a research note on Friday, November 28th. Finally, Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.50.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.